Ixekizumab (Taltz)

OFFICE / HOME HEALTH/ SELF ADMINISTRATION

Indications for Prior Authorization:
  • Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Patients must meet the following criteria for the indications above:
  • Diagnosis of chronic moderate-to-severe plaque psoriasis confirmed by a dermatologist or rheumatologist (psoriasis affects 10% or more of the body; psoriasis involves hands, feet, head, and neck or genitalia), AND
  • Prescribed by dermatologist or rheumatologist, AND
  • Patient has tried and failed topical therapy (e.g., Dovonox, Tazorac, other topical steroids), AND
  • Documented failure or clinically significant adverse effects to one of the following therapies alone or in combination, unless contraindicated: methotrexate (doses up to 15-20 mg per week) or (if methotrexate is contraindicated) cyclosporine, aceitretin, or a trial with PUVA or UVB, AND
  • Documented failure or clinically significant adverse effects to at least two of the following: Humira, Otezla, Stelara or Cosentyx
Dosing:
  • 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, then 80 mg every 4 weeks
Approval:
  • One year to assess patient's response
Risk of Tuberculosis:

Patients should be evaluated for latent tuberculosis infection with a TB skin test.  Treatment of latent tuberculosis infection should be initiated prior to therapy with Taltz

 

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar